Key Takeaways:
Spyre Therapeutics' TL1A antibody SPY072 hit statistical significance on RA endpoints in Phase 2 but fell short of the company's bar for monotherapy, pushing the program toward combination use across autoimmune indications.
"The results today do not lead us to prioritize SPY072 as a monotherapy in RA," Cameron Turtle, chief executive officer at Spyre, said. "The favorable safety profile of TL1A inhibition alongside demonstrated efficacy across inflammatory bowel disease, HS, and now RA provide increased conviction that our long-acting TL1A antibodies have potential in a range of autoimmune diseases and as optimal combination components."
In the SKYWAY-RA sub-study (NCT07148414), low-dose SPY072 reduced DAS28-CRP by 1.9 points at Week 12 versus 1.3 for placebo (p<0.05). High dose achieved 63 percent ACR20 response versus 43 percent for placebo (nominal p<0.05). Both doses achieved complete and durable suppression of free TL1A through Week 12, confirming full target engagement.
The company now redirects SPY072 toward combination therapy, having initiated the SKYLIGHT trial pairing it with an IL-17A/F antibody in hidradenitis suppurativa, with topline data expected in late 2027 or early 2028. Additional SKYWAY readouts in psoriatic arthritis and axial spondyloarthritis are due in the fourth quarter of 2026.
The SKYWAY-RA sub-study enrolled 143 patients with moderate to severely active RA who had inadequate responses to conventional or advanced therapies. Results were generally comparable between advanced-therapy-naive and advanced-therapy-experienced subgroups, suggesting the drug's effect is not limited to a particular patient population.
SPY072 is a long-acting antibody targeting TL1A, a cytokine that drives inflammation across multiple autoimmune diseases. TL1A signaling promotes the production of inflammatory cytokines and has been implicated in the pathology of IBD, RA, and other immune-mediated conditions. The SKYWAY basket design allowed Spyre to test the mechanism across several rheumatic conditions simultaneously, identifying where TL1A inhibition delivers the strongest clinical benefit.
The RA outcome places Spyre in a competitive field where TL1A-targeted therapies have drawn significant investment. Merck, Pfizer, and Roche have all advanced programs in this space, primarily focused on inflammatory bowel disease, where TL1A inhibition has shown some of the strongest clinical signals. Spyre's differentiation rests on extended half-life engineering and rational combination strategies rather than competing head-to-head in a single indication. The company's approach pairs established mechanisms — such as TL1A with IL-17A/F — to target complementary inflammatory pathways in diseases where single-agent responses remain incomplete.
Safety profile
Safety data showed SPY072 was well tolerated, with adverse event rates of 27 percent on active treatment versus 36 percent on placebo. One serious treatment-emergent adverse event occurred on each arm, none deemed drug-related. One death occurred in a participant receiving placebo. The most common adverse events were infections, occurring in 14 percent of SPY072-treated participants and 15 percent of placebo-treated participants. The safety profile was consistent with the broader TL1A class.
The company's broader pipeline includes extended half-life antibodies targeting α4β7, IL-23, and IL-17A/F, with combination programs across inflammatory bowel disease and hidradenitis suppurativa. The SKYLINE Part A trial in ulcerative colitis with SPY003 is expected to read out in September 2026, followed by Part B results in 2027 across six assets. These upcoming readouts will help determine which programs advance and which combinations offer the strongest differentiation.
For investors, the mixed RA outcome creates a nuanced picture. The efficacy signal confirms TL1A inhibition works in RA, but the magnitude relative to placebo did not clear the company's threshold for monotherapy development. Spyre's strategy now hinges on whether SPY072 performs better as a combination component, particularly in HS where the IL-17A/F pairing targets complementary inflammatory pathways. SYRE shares will likely react to how the market weighs the positive proof-of-mechanism against the deprioritization of a potential monotherapy indication. The next 12 to 18 months bring multiple data readouts that will test whether Spyre's combination-first strategy can deliver the differentiation that monotherapy could not.
This article is for informational purposes only and does not constitute investment advice.
